

## SUPPLEMENTARY TABLES

**Supplementary Table 1.** Responses to daratumumab and pomalidomide combinations

<b>Responses</b>	<b>Responses to prior daratumumab combinations N=30 (%)</b>	<b>Current responses to pomalidomide combinations N=30 (%)</b>
CR	0	2 (7%)
VGPR	3 (10%)	3 (10%)
PR	8 (27%)	11 (37%)
MR	0	1 (3%)
SD	5 (17%)	8 (27%)
PD	13 (43%)	5 (17%)
NA	1 (3%)	0
ORR	11 (37%)	16 (53%)
CBR	11 (37%)	17 (57%)
DCR	16 (53%)	25 (83%)

CR: complete response; VGPR: very good partial response; PR: partial response; MR: minimal response; SD: stable disease; PD: progressive disease

ORR: overall response rate ( $\geq$ PR); CBR: clinical benefit rate ( $\geq$ MR); DCR: disease control rate ( $\geq$ SD)

**Supplementary Table 2.** Responses to daratumumab and pomalidomide combinations in patients with extramedullary myeloma

<b>Responses</b>	<b>Responses to prior daratumumab combinations N=7 (%)</b>	<b>Current responses to pomalidomide combinations N=7 (%)</b>
CR	0	1 (14%)
VGPR	1 (14%)	0
PR	1 (14%)	3 (43%)
MR	0	1 (14%)
SD	0	1 (14%)
PD	5 (71%)	1 (14%)
ORR	2/7 (28%)	4/7 (57%)
CBR	2/7 (28%)	5/7 (71%)
DCR	2/7 (28%)	6/7 (86%)

CR: complete response; VGPR: very good partial response; PR: partial response; MR: minimal response; SD: stable disease; PD: progressive disease

ORR: overall response rate ( $\geq$ PR); CBR: clinical benefit rate ( $\geq$ MR); DCR: disease control rate ( $\geq$ SD)